A long-term Phase III study confirms the safety of Pfizer's (PFE) ALO-02 capsules for treating...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

A long-term Phase III study confirms the safety of Pfizer's (PFE) ALO-02 capsules for treating patients with moderate-to-severe chronic, non-cancer pain. The "adverse event profile" was as expected, with the most common side effects - in over 10% of the 395 patients in the study - being nausea, constipation, vomiting and headache. (PR)